New and Emerging Oncotherapeutic Neurotoxicity
New and Emerging Oncotherapeutic Neurotoxicity (NEON) study day
Supported by the Immuno-Oncology Clinical Network (IOCN)
Join us for the New and Emerging Oncotherapeutic Neurotoxicity (NEON) Study Day, a one-day educational event supported by the Immuno-Oncology Clinical Network (IOCN), taking place on Friday 11 September 2026 at the National Hospital for Neurology and Neurosurgery, London. Bringing together leading experts in neurology, oncology and immunotherapy toxicity, the programme will explore the evolving landscape of cancer immunotherapies and the recognition and management of new and emerging neurotoxicities. Through expert lectures, rapid-fire clinical scenarios, live MDT discussions and networking opportunities, this study day offers valuable insights for consultants, trainees and allied health professionals involved in the care of patients receiving modern oncological therapies.
Location
33 Queen Square, Lower Ground Lecture theatre
National Hospital for Neurology and Neurosurgery, London
WC1N 3BG
Friday 11th September 2026
Consultants: 50
Trainees and AHPs: 30
CPD points to be confirmed
Programme
0900-0930: Registration and coffee
Introduction
0930-1000: Evolving Landscape of Immunotherapies in Cancer (Professor Anna Olsson-Brown, consultant medical oncologist, UPMC Professor of Cancer Clinical Trials, University College Cork)
1000-1030: New and Emerging Oncotherapeutic Neurotoxicities (Dr Aisling Carr, consultant neurologist NHNN, London)
Rapid fire clinical scenarios 1
1030-1045: IO-neuritis (Dr Ryan Keh, consultant neurologist, Salford Royal, Manchester)
1045-1100: Triple M Syndrome (Dr Ben Schroeder, neurology registrar, University Hospital of Wales, Cardiff)
1100-1130:Coffee
Rapid fire clinical scenarios 2
1130-1145: IO-CNS manifestations (Dr Clara Tierney, NHNN)
1145-1200:IO-HLH (Dr Jess Manson, consultant rheumatologist, University College London Hospitals)
1200-1215: Rare and Atypical IO-Neurotoxicity Presentations (Dr Heather Shaw, consultant medical oncologist, UCLH and Mount Vernon Cancer centre)
1215-1230:Common Non-Neurological IO-Toxicities (Dr Kate Young, consultant oncologist, Royal Marsden Hospital)
1230-1300: IO-neurotoxicity mimics and chameleons (Dr Aisling Carr, consultant neurologist, NHNN)
1300-1400: Lunch and Networking
1400-1500: IO-neurotoxicity live MDT: 2 cases and live discussion
1500-1530:Coffee
Rechallenge and Non-IO Neurotoxicities
1530-1550: Risks and considerations of ICI in neurological autoimmune disease and rechallenge (Dr Mark Willis, consultant neurologist, University Hospital of Wales, Cardiff)
1550-1610:CAR-T neurotoxicity (Dr Frederick Vonberg, consultant neurologist, NHNN)
1610-1640 Beyond ICI and CAR-T (Dr Nick Davies, consultant neurologist, Chelsea and Westminster Hospital).
1640-1700: Panel Discussion
Read more